Gapping up
In reaction to earnings/guidance:
- PUBM +27%, RNG +25.8% (also strategic partnership with Mitel; also CFO stepping down), DASH +16.5% (also to acquire Wolt in an all-stock deal valued at € 7.0 bln), STEM +16.2%, FVRR +15.1%, JXN +14.9% (also commences dividend; authorizes $300 mln share repurchase program), SAIL +14.1%, SEMR +13.9%, NARI +13.1%, IS +11.3%, SGFY +10.9%, AVID +10.2%, VCYT +7.8%, FOUR +7.3%, FLGT +6.8%, LGND +6.5% (also pursuing plans for OmniAb to become a standalone public co), FGEN +6.1%, CARG +6.1%, LU +6%, ZETA +5.9%, DNUT +5.9%, NVEE +5.7%, CERT +5.4%, FLYW +4.8%, TWOU +4.7%, PFGC +4.5%, ELY +4.4%, RPAY +3.9%, GOCO +3.9%, SHCR +3.9%, MNKD +3.8%, SFL +3.7%, CCXI +3.4%, PAR +3.4%, VET +3.3%, CNR +3.2% (also to acquire Union Corrugating Co), SCSC +2.6%, ARLO +2.3%, VZIO +1.2%, AER +1.2%, INO +1%
Other news:
- VALN +21.5% (European Commission has approved an agreement pursuant to which Valneva would supply up to 60 mln doses of VLA2001 over two years including approximately 27 mln doses in 2022)
- IMAB +8.1% (forms strategic commercial partnership with Jumpcan for eftansomatropin alfa)
- DNAY +7.2% (to acquire Eton Bioscience for $13 mln in cash)
- ADV +5.6% (announces $100 mln share repurchase plan)
- CVAC +4.4% (presents promising data at SITC from Phase 1 Study of oncology candidate CV8102 showing systemic immune response)
- GRTS +3.9% (preclinical data in non-human primate models from the CORAL next-generation COVID-19 vaccine program against SARS-CoV-2)
- PFSW +1.5% (issues timing update for late 10-Q; reiterates previously stated outlook)
- KDNY +1.3% (prices offering of 7828572 shares of common stock at $14.00 per share)
- KVSA +1.1% (private placement related to business combination with Valo Health expands)
- CPTK +1% (Crown Proptech Acquisitions inks SPAC merger agreement with cloud-based smart building firm Brivo)
Analyst comments:
- UBX +8.9% (upgraded to Buy from Neutral at Mizuho; tgt raised to $7)
- GE +1.4% (upgraded to Buy from Hold at Deutsche Bank)